Literature DB >> 26159421

Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expression.

David Kozono1, Jie Li2, Masayuki Nitta1, Oltea Sampetrean3, David Gonda2, Deepa S Kushwaha1, Dmitry Merzon1, Valya Ramakrishnan2, Shan Zhu1, Kaya Zhu1, Hiroko Matsui4, Olivier Harismendy4, Wei Hua5, Ying Mao5, Chang-Hyuk Kwon6, Hideyuki Saya3, Ichiro Nakano6, Donald P Pizzo7, Scott R VandenBerg7, Clark C Chen8.   

Abstract

The available evidence suggests that the lethality of glioblastoma is driven by small subpopulations of cells that self-renew and exhibit tumorigenicity. It remains unclear whether tumorigenicity exists as a static property of a few cells or as a dynamically acquired property. We used tumor-sphere and xenograft formation as assays for tumorigenicity and examined subclones isolated from established and primary glioblastoma lines. Our results indicate that glioblastoma tumorigenicity is largely deterministic, yet the property can be acquired spontaneously at low frequencies. Further, these dynamic transitions are governed by epigenetic reprogramming through the lysine-specific demethylase 1 (LSD1). LSD depletion increases trimethylation of histone 3 lysine 4 at the avian myelocytomatosis viral oncogene homolog (MYC) locus, which elevates MYC expression. MYC, in turn, regulates oligodendrocyte lineage transcription factor 2 (OLIG2), SRY (sex determining region Y)-box 2 (SOX2), and POU class 3 homeobox 2 (POU3F2), a core set of transcription factors required for reprogramming glioblastoma cells into stem-like states. Our model suggests epigenetic regulation of key transcription factors governs transitions between tumorigenic states and provides a framework for glioblastoma therapeutic development.

Entities:  

Keywords:  epigenomics; glioblastoma; neoplastic stem cells

Mesh:

Substances:

Year:  2015        PMID: 26159421      PMCID: PMC4522819          DOI: 10.1073/pnas.1501967112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  72 in total

1.  Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome.

Authors:  Nathaniel D Heintzman; Rhona K Stuart; Gary Hon; Yutao Fu; Christina W Ching; R David Hawkins; Leah O Barrera; Sara Van Calcar; Chunxu Qu; Keith A Ching; Wei Wang; Zhiping Weng; Roland D Green; Gregory E Crawford; Bing Ren
Journal:  Nat Genet       Date:  2007-02-04       Impact factor: 38.330

2.  SOX2 expression levels distinguish between neural progenitor populations of the developing dorsal telencephalon.

Authors:  Scott R Hutton; Larysa H Pevny
Journal:  Dev Biol       Date:  2011-01-21       Impact factor: 3.582

3.  Survival of human cells in the aggregate form: potential index of in vitro cell transformation.

Authors:  A F Steuer; J S Rhim; P M Hentosh; R C Ting
Journal:  J Natl Cancer Inst       Date:  1977-04       Impact factor: 13.506

4.  Long term culture of normal and neoplastic human glia.

Authors:  J Pontén; E H Macintyre
Journal:  Acta Pathol Microbiol Scand       Date:  1968

5.  Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties.

Authors:  Jing Wang; Fei Lu; Qi Ren; Hong Sun; Zhengshuang Xu; Rongfeng Lan; Yuqing Liu; David Ward; Junmin Quan; Tao Ye; Hui Zhang
Journal:  Cancer Res       Date:  2011-10-05       Impact factor: 12.701

Review 6.  Nature, nurture, or chance: stochastic gene expression and its consequences.

Authors:  Arjun Raj; Alexander van Oudenaarden
Journal:  Cell       Date:  2008-10-17       Impact factor: 41.582

7.  Reprogramming of human somatic cells to pluripotency with defined factors.

Authors:  In-Hyun Park; Rui Zhao; Jason A West; Akiko Yabuuchi; Hongguang Huo; Tan A Ince; Paul H Lerou; M William Lensch; George Q Daley
Journal:  Nature       Date:  2007-12-23       Impact factor: 49.962

8.  Modeling Adult Gliomas Using RCAS/t-va Technology.

Authors:  Dolores Hambardzumyan; Nduka M Amankulor; Karim Y Helmy; Oren J Becher; Eric C Holland
Journal:  Transl Oncol       Date:  2009-05       Impact factor: 4.243

9.  MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development.

Authors:  Johnny C Akers; Valya Ramakrishnan; Ryan Kim; Johan Skog; Ichiro Nakano; Sandeep Pingle; Juliya Kalinina; Wei Hua; Santosh Kesari; Ying Mao; Xandra O Breakefield; Fred H Hochberg; Erwin G Van Meir; Bob S Carter; Clark C Chen
Journal:  PLoS One       Date:  2013-10-21       Impact factor: 3.240

10.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

View more
  26 in total

1.  CNS Anticancer Drug Discovery and Development: 2016 conference insights.

Authors:  Victor A Levin; Lauren E Abrey; Timothy P Heffron; Peter J Tonge; Arvin C Dar; William A Weiss; James M Gallo
Journal:  CNS Oncol       Date:  2017-07-18

2.  The NSL Chromatin-Modifying Complex Subunit KANSL2 Regulates Cancer Stem-like Properties in Glioblastoma That Contribute to Tumorigenesis.

Authors:  Nazarena E Ferreyra Solari; Fiorella S Belforte; Lucía Canedo; Guillermo A Videla-Richardson; Joaquín M Espinosa; Mario Rossi; Eva Serna; Miguel A Riudavets; Horacio Martinetto; Gustavo Sevlever; Carolina Perez-Castro
Journal:  Cancer Res       Date:  2016-07-12       Impact factor: 12.701

Review 3.  Developmental origins and oncogenic pathways in malignant brain tumors.

Authors:  Q Richard Lu; Lily Qian; Xianyao Zhou
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2019-04-03       Impact factor: 5.814

4.  Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway.

Authors:  G R Sareddy; S Viswanadhapalli; P Surapaneni; T Suzuki; A Brenner; R K Vadlamudi
Journal:  Oncogene       Date:  2016-11-28       Impact factor: 9.867

Review 5.  Epigenetic regulation of cancer stem cell and tumorigenesis.

Authors:  Kezhou Zhu; Victoria Xie; Suyun Huang
Journal:  Adv Cancer Res       Date:  2020-07-16       Impact factor: 6.242

6.  A single-cell translocation and secretion assay (TransSeA).

Authors:  Wei Cai; Yu-Jui Chiu; Valya Ramakrishnan; Yihuan Tsai; Clark Chen; Yu-Hwa Lo
Journal:  Lab Chip       Date:  2018-10-09       Impact factor: 6.799

7.  Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors.

Authors:  Yuyu He; Jie Li; Tomoyuki Koga; Jun Ma; Sanjay Dhawan; Yuta Suzuki; Frank Furnari; Varun V Prabhu; Joshua E Allen; Clark C Chen
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300

Review 8.  Cancer metabolism as a central driving force of glioma pathogenesis.

Authors:  Kenta Masui; Webster K Cavenee; Paul S Mischel
Journal:  Brain Tumor Pathol       Date:  2016-06-13       Impact factor: 3.298

9.  PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response.

Authors:  Jie Li; Megan M Kaneda; Jun Ma; Ming Li; Ryan M Shepard; Kunal Patel; Tomoyuki Koga; Aaron Sarver; Frank Furnari; Beibei Xu; Sanjay Dhawan; Jianfang Ning; Hua Zhu; Anhua Wu; Gan You; Tao Jiang; Andrew S Venteicher; Jeremy N Rich; Christopher K Glass; Judith A Varner; Clark C Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-20       Impact factor: 11.205

10.  Molecular mechanisms of OLIG2 transcription factor in brain cancer.

Authors:  Igor F Tsigelny; Valentina L Kouznetsova; Nathan Lian; Santosh Kesari
Journal:  Oncotarget       Date:  2016-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.